Does Betaseron Work for Multiple Sclerosis?
Betaseron (interferon beta-1b) reduces relapse rates and delays disability progression in relapsing-remitting multiple sclerosis (RRMS). In the pivotal 1993 phase 3 trial of 372 patients, it cut annualized relapse rates by 34% versus placebo over two years (1.31 vs. 1.82 relapses/year), with MRI showing 86% fewer new or enlarging lesions.[1][2] Long-term follow-up data confirm sustained benefits, including slower time to confirmed disability progression.[3]
How Effective Is It Compared to Placebo and Other Treatments?
Against placebo, Betaseron shows consistent relapse reduction (20-30% across studies) and lesion activity decrease on MRI.[1][4] Real-world evidence from registries like the MSBase cohort (over 10,000 patients) links it to lower relapse risk versus untreated patients, though newer therapies like ocrelizumab outperform it (e.g., 46-47% relapse reduction in OPERA trials).[5][6] It remains a first-line option per AAN guidelines for active RRMS.
Who Does Betaseron Help Most?
It works best in early RRMS with frequent relapses or high MRI activity. Patients with secondary progressive MS see limited benefit, per INCOMIN and European trials showing no significant disability delay.[7] Response predictors include younger age, lower baseline disability (EDSS <3.5), and early treatment start.[8]
What If It Doesn't Work for Someone?
About 20-30% of patients have breakthrough disease after 2 years; switching to higher-efficacy drugs like fingolimod or natalizumab improves outcomes in studies like TRANSFORMS and TENERE.[9][10] Monitoring via MRI and clinical exams guides decisions.
Common Side Effects and Risks
Flu-like symptoms affect 60-80% initially (fever, chills, managed with dose titration and NSAIDs). Injection-site reactions occur in 70%; liver enzyme elevations in 10-20%; rare severe risks include depression (5%) and neutralizing antibodies (30-40% by year 2, reducing efficacy by 20-30%).[2][11] Neutralizing antibodies decline over time in many cases.[12]
How Is Betaseron Administered and What's the Cost?
Subcutaneous injections every other day (0.25 mg), self-administered after training. Annual U.S. list price exceeds $70,000; patient assistance programs from Bayer reduce out-of-pocket costs.[13]
[1]: Pivotal Betaseron Trial (NEJM 1993)
[2]: Betaseron Prescribing Information (Bayer)
[3]: Long-term Betaseron Follow-up (Neurology 2006)
[4]: Cochrane Review on Interferon Beta (2017)
[5]: MSBase Registry Data (Neurology 2018)
[6]: OPERA Trials for Ocrelizumab (NEJM 2017)
[7]: INCOMIN Trial (Neurology 2001)
[8]: Predictors of Response (Lancet Neurol 2010)
[9]: TRANSFORMS Trial (NEJM 2010)
[10]: TENERE Trial (Lancet Neurol 2014)
[11]: FDA Adverse Event Data
[12]: Antibody Impact Study (Neurology 2003)
[13]: Drugs.com Pricing